Diarrhea News and Research

Latest Diarrhea News and Research

Patients with celiac disease face increased risk of mortality

New research indicates that patients with lesser degrees of celiac disease-related symptoms, such as intestinal inflammation or latent celiac disease, have a modestly increased risk of death, according to a study in the September 16 issue of JAMA.

16 Sep 2009

Optimer's North American phase 3 Fidaxomicin study results presented at the 49th ICAAC

Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that new data highlighting fidaxomicin's (OPT-80) lower CDI recurrence rates and reduced risk of vancomycin-resistant enterococci (VRE) acquisition from Optimer's North American phase 3 study were presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.

16 Sep 2009

Also in Global Health News: PNG, Nepal outbreaks; Taliban Oks polio vaccination; Technology helps in developing countries; Satellite images for malaria control

VOA News examines the ongoing struggle for Papua New Guinea's health system to treat thousands of people infected by the "simultaneous outbreaks of influenza, dysentery and cholera that have killed about 120 people." The article includes information about the difficulties heath officials are having in assessing the various outbreaks and concerns of medical workers that conditions may soon worsen (Mercer, 9/14).

16 Sep 2009

Alvine Pharmaceuticals raises funds for Phase 2a clinical trial of its lead compound ALV003

Alvine Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on developing and commercializing therapeutics for autoimmune/gastrointestinal diseases, today announced the closing of a $21.5 million extension of its Series A financing.

15 Sep 2009

Anti-fungal pill found to be effective for treating oral candidiasis

A once-daily medication option for treating the most common mouth infection in HIV/AIDS patients has shown to be just as effective and safe as taking an anti-fungal pill five times a day, according to a Henry Ford Hospital study.

15 Sep 2009

Innovative treatments for bowel dysfunction

Twenty percent of all Albertans are plagued by symptoms of diarrhea, constipation, abdominal pain, bloating, and gas. More than an inconvenience for many, these problems are rarely discussed in public, leaving sufferers feeling isolated. Yet bowel symptoms can be disabling, greatly impairing quality of life.

15 Sep 2009

IBC offers coverage for H1N1 and seasonal flu vaccines

In an effort to help keep members healthy and flu-free this year, Independence Blue Cross (IBC) will offer coverage for the administration costs of the H1N1 (swine flu) vaccine when it becomes available. In addition, IBC will continue to cover seasonal flu vaccine.

15 Sep 2009

Phase 2b clinical trial results of Dextofisopam to treat irritable bowel syndrome announced

Pharmos Corporation (Pink Sheets: PARS) announced today the results of its Phase 2b Dextofisopam clinical trial to evaluate safety and efficacy of the compound in irritable bowel syndrome.

14 Sep 2009

Phase 3 results of TARGET 1 and TARGET 2 clinical trials released

Salix Pharmaceuticals, Ltd. today announced the successful outcome of two Phase 3, randomized, double-blind, placebo-controlled, multicenter trials, TARGET 1 and TARGET 2, designed to evaluate the efficacy and safety of rifaximin 550 mg TID in the treatment of patients with non-constipation irritable bowel syndrome (non-C IBS).

14 Sep 2009

Influenza patients treated with Tamiflu has higher survival rates

Roche announced today that two new observational studies concluded that influenza patients treated with Tamiflu(R) (oseltamivir phosphate) had significantly higher survival rates than untreated patients.

14 Sep 2009

FDA approves Theravance's VIBATIV for treating complicated skin and skin structure infections

Theravance, Inc. (NASDAQ: THRX) and Astellas Pharma US, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved VIBATIV™ (telavancin) for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains.

14 Sep 2009

Cymbalta maintains reduction in pain for patients with chronic low back pain

New data show patients with chronic low back pain on Cymbalta(R) (duloxetine HCl) maintained reductions in pain for 41 weeks. In patients who initially responded to duloxetine, this maintenance of pain reduction was accompanied by further reduction in pain that was statistically significant as measured by the Brief Pain Inventory (BPI) average pain rating.

11 Sep 2009

Merck update on the status of telcagepant clinical development programs

Merck & Co., Inc. today updated the status of the clinical development programs for telcagepant (MK-0974) and MK-3207, the Company's investigational oral calcitonin gene-related peptide (CGRP) receptor antagonists for the intermittent treatment of acute migraine.

11 Sep 2009

Under-five mortality rate continues to decline

UNICEF today released new figures that show the rate of deaths of children under five years of age continued to decline in 2008.

11 Sep 2009

Students do not comply with basic preventative measures to combat H1N1

As public health experts warn of potential widespread outbreaks of H1N1 flu this school year, a new study from North Carolina State University shows that students do not comply with basic preventative measures as much as they think do. In other words, the kids aren't washing their hands.

11 Sep 2009

FDA approves Supplemental New Drug Application for DOXIL

Centocor Ortho Biotech Products, L.P. today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its Supplemental New Drug Application (sNDA) for DOXIL (doxorubicin HCI liposome injection) in combination with docetaxel for the treatment of women with locally advanced and metastatic breast cancer.

10 Sep 2009

UNICEF data shows global child mortality now below 9m, progress not enough to achieve MDG in most regions

The annual number of deaths among children younger than five worldwide "has fallen below nine million" compared with 12.5 million in 1990, according to new data from UNICEF, the New York Times reports. "That's 10,000 less children dying per day," Ann Veneman, UNICEF's executive director, said.

10 Sep 2009

South East Asian health ministers adopt declaration to improve disaster preparedness, address childhood diarrhea

Health ministers from 11 member states in the WHO's South East Asian region on Tuesday at the 62nd session of the WHO Regional Committee for South East Asia adopted the Kathmandu Declaration on Protecting Health Facilities from Disasters, which commits them to make health facilities better prepared for health emergencies, Republica reports.

10 Sep 2009

Caldolor launched ahead of schedule in U.S. by Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced today that it has successfully implemented the U.S. launch of Caldolor((R)), an intravenous formulation of ibuprofen, designed primarily for use in the hospital setting.

9 Sep 2009

Ceragenix awarded $2.87M NIH grant to develop a drug for treating Clostrdium difficile and Shigella

Ceragenix Pharmaceuticals, Inc. (“Ceragenix”) (OTCBB:CGXP), a medical device company focused on infectious disease and dermatology, today announced that the National Institutes of Health (“NIH”) has awarded a $2.87 million grant to fund the pre clinical development of a Ceragenin™based oral drug to treat two common and potentially deadly gastrointestinal infections: Clostrdium difficile and Shigella.

9 Sep 2009

Diarrhea News and Research

Latest Diarrhea News and Research

Patients with celiac disease face increased risk of mortality

Optimer's North American phase 3 Fidaxomicin study results presented at the 49th ICAAC

Also in Global Health News: PNG, Nepal outbreaks; Taliban Oks polio vaccination; Technology helps in developing countries; Satellite images for malaria control

Alvine Pharmaceuticals raises funds for Phase 2a clinical trial of its lead compound ALV003

Anti-fungal pill found to be effective for treating oral candidiasis

Innovative treatments for bowel dysfunction

IBC offers coverage for H1N1 and seasonal flu vaccines

Phase 2b clinical trial results of Dextofisopam to treat irritable bowel syndrome announced

Phase 3 results of TARGET 1 and TARGET 2 clinical trials released

Influenza patients treated with Tamiflu has higher survival rates

FDA approves Theravance's VIBATIV for treating complicated skin and skin structure infections

Cymbalta maintains reduction in pain for patients with chronic low back pain

Merck update on the status of telcagepant clinical development programs

Under-five mortality rate continues to decline

Students do not comply with basic preventative measures to combat H1N1

FDA approves Supplemental New Drug Application for DOXIL

UNICEF data shows global child mortality now below 9m, progress not enough to achieve MDG in most regions

South East Asian health ministers adopt declaration to improve disaster preparedness, address childhood diarrhea

Caldolor launched ahead of schedule in U.S. by Cumberland Pharmaceuticals

Ceragenix awarded $2.87M NIH grant to develop a drug for treating Clostrdium difficile and Shigella

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Diarrhea News and Research

Latest Diarrhea News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in